Printer Friendly

STERLING WINTHROP DEDICATES PHARMACEUTICALS RESEARCH AND DEVELOPMENT CENTER IN UPPER PROVIDENCE TOWNSHIP, PA.

 UPPER PROVIDENCE TOWNSHIP, Pa., May 10 /PRNewswire/ -- In ceremonies that stressed the company's promising future in discovering and developing innovative treatments for the unmet medical needs of mankind, Sterling Winthrop Inc. today dedicated its Pharmaceuticals Research and Development Center, located in Upper Providence Township (UPT), Pa. (outside of Philadelphia). The state-of-the-art facility will serve as the new U.S. headquarters of the Sterling Winthrop Pharmaceuticals Research Division's (SWPRD) R&D efforts.
 Nobel Laureate Linus Pauling, Ph.D., and William N. Kelley, M.D., chief executive officer of the University of Pennsylvania Medical Center and Dean of the School of Medicine, were the keynote speakers at the dedication ceremony. The Hon. Robert P. Casey, Governor of Pennsylvania, also spoke at the dedication. The ceremony began a week- long celebration, which includes a scientific symposium featuring an international delegation of scientists and dignitaries.
 Also highlighting the program were remarks from Louis P. Mattis, Sterling Winthrop chairman, president and CEO; Kay R. Whitmore, chairman, president and CEO of Eastman Kodak Company; Eugene H. Cordes, Ph.D., Sterling Winthrop vice president and president, Sterling Winthrop Pharmaceuticals Research Division; and Alastair Ross, UPT Project Director and SWPRD senior vice president, Administration.
 At the conclusion of the presentations, a dedication plaque was unveiled which read: "Where the Promise Becomes Reality ... To further our mission to discover and develop distinctive pharmaceutical solutions for the health care needs of mankind, Sterling Winthrop Inc. dedicates this center to research and development excellence."
 Where the Promise Becomes Reality
 Sterling Winthrop and Kodak executives stressed scientific excellence and the company's re-emergence as a global leader in pharmaceuticals in remarks to an audience of 300 guests and dignitaries.
 "Today ... we dedicate a facility where excellence in science is destined to result in significant advances for the health care needs of mankind ... a place where the promise of treatment and cure will become a reality," said Mattis.
 "In addition to a dedication, we also celebrate the transformation of our company into an emerging global leader in the pharmaceuticals and consumer health products industries," continued Mattis. "This state-of- the-art facility is a symbol of our commitment to leadership in pharmaceutical R&D, and a symbol of the renewed vigor, focus and success that is Sterling Winthrop."
 Kay R. Whitmore, Kodak chairman, president and CEO, told those in attendance, "We at Kodak are proud of the accomplishments of Sterling Winthrop ... and proud of its contributions to the success of our Health Group. This facility represents the scientific excellence necessary to bring distinctive pharmaceutical products from the lab to the patient."
 Eugene Cordes, Ph.D., Sterling Winthrop vice president and president of the Sterling Winthrop Pharmaceuticals Research Division, said, "The facility will enable our researchers and scientists to continue their progress toward our mission: the discovery and development of distinctive pharmaceuticals that meet the health care needs of mankind."
 Facilities
 The new R&D facility includes approximately 1 million square feet of laboratories, offices, library, auditorium and conference space in a series of nine low-rise buildings on the 161-acre site. The emphasis in developing the campus-like setting was on open, green spaces that maintain the character and landscape of the area and its natural state where possible.
 Construction began in October of 1990, with the midpoint in the construction celebrated one year later in 1991. Scientists and support staff began moving into the site in October of 1992, and when it is complete later this year, the facility will house approximately 1,200 people.
 The UPT facility consolidates SWPRD's U.S. research and development operations to two sites in Pennsylvania -- UPT and the Great Valley Corporate Center. SWPRD also has research facilities in Alnwick, U.K., and Dijon, France.
 Sterling Winthrop announced in May 1989 that it was consolidating its research facilities in Southeastern Pennsylvania. The UPT project team included experts from Sterling Winthrop, the architects and engineers of Philadelphia-based The Kling-Lindquist Partnership, Inc. and Life Sciences International, and construction managers from Gilbane Building Company. The team earned several awards including the 1991 Cooperator/Developer of the Year Award from the Montgomery County Conservation District, the 1991-92 Conservation Award from the Perkiomen Valley Watershed Association, and has been named the 1993 Project of the Year by the Philadelphia Area Labor-Management Committee.
 Sterling Winthrop's pharmaceutical research and development expenditures, as a result of the company's alliance with French-based Elf Sanofi, rank among the top 12 in the industry at more than one-half billion annually. In December of 1992, Sterling Winthrop described a robust pipeline of products that includes innovative diagnostic imaging agents and distinctive treatments for brain and other cancers, heart disease, osteoporosis and prostate disorders, among others.
 Sterling Winthrop Inc. is a global developer, manufacturer and marketer of pharmaceuticals and consumer health products. With headquarters in New York City, Sterling Winthrop is a subsidiary of Eastman Kodak Company (NYSE: EK).
 -0- 5/10/93
 /CONTACT: Carol J. Perlman, 212-907-2724, or Terry G. Kelley, 212-907-3009, both of Sterling Winthrop/
 (EK)


CO: Sterling Winthrop ST: Pennsylvania IN: MTC SU:

TS-OS -- NY055 -- 6594 05/10/93 15:16 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 10, 1993
Words:840
Previous Article:STATESWEST REPORTS APRIL TRAFFIC RESULTS
Next Article:STERLING WINTHROP SCIENCE FELLOWSHIP PROGRAM UNVEILED AT DEDICATION OF PHARMACEUTICAL RESEARCH DIVISION R&D CENTER IN UPPER PROVIDENCE TOWNSHIP
Topics:


Related Articles
SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING, DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL
DR. JONAS SALK, ELIE WIESEL HIGHLIGHT DEDICATION OF RPR'S RESEARCH AND CORPORATE HEADQUARTERS; AIDS BENEFIT FEATURES BACHARACH, WARWICK, FLACK
SALK, WIESEL HIGHLIGHT DEDICATION OF HEADQUARTERS FOR RHONE-POULENC RORER; BACHARACH, WARWICK, FLACK AND BOOSLER HEADLINE AIDS BENEFIT
STERLING WINTHROP ANNOUNCES MAY 10 DEDICATION OF PHARMACEUTICAL R&D CENTER IN UPPER PROVIDENCE TOWNSHIP, PA.; PAULING AND KELLEY TO SPEAK
STERLING WINTHROP SCIENCE FELLOWSHIP PROGRAM UNVEILED AT DEDICATION OF PHARMACEUTICAL RESEARCH DIVISION R&D CENTER IN UPPER PROVIDENCE TOWNSHIP
BRISTOL-MYERS SQUIBB, STERLING WINTHROP INC. AND ELF SANOFI ANNOUNCE CARDIOVASCULAR DEVELOPMENT EFFORT
KODAK COMPLETES SALE OF STERLING WINTHROP PHARMACEUTICALS BUSINESS TO SANOFI
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION
KODAK COMPLETES STERLING WINTHROP SALE TO SMITHKLINE BEECHAM
SMITHKLINE BEECHAM ACQUIRES PHARMACEUTICAL R&D FACILITY FROM EASTMAN KODAK

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters